GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2006

Ablynx Licenses Nanobodies to Wyeth for Clinically Validated Target

  • Ablynx and Wyeth Pharmaceuticals will team up to discover, develop, and commercialize Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas, under an exclusive research collaboration and license agreement with.

    Ablynx has granted Wyeth exclusive, worldwide rights to Nanobodies targeting the clinically validated target tumor necrosis factor alpha. The companies will together advance these biologics through preclinical development.

    Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialization of multiple products. This includes initial payment, research support, and milestone payments. In addition Ablynx will receive royalties on product sales.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?